【中国抗体-B(03681.HK)：自愿撤回舒西利单抗在中国用于治疗RA的BLA申请】智通财经APP讯，中国抗体-B(03681.HK)发布公告，诚如公司日期为2023年4月26日及2023年9月5日的公告所披露，舒西利单抗在中国治疗类风湿关节炎(RA)的III期临床研究中达到主要终点，并已向中华人民共和国国家药品监督管理局提交生物制品上市许可申请(BLA)申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.